Skip to main content
Zensei
Trailing the market and pharmaceutical stocks

Novo Nordisk (NVO) stock vs the S&P 500 and pharmaceutical stocks

As of 20 November 2026, Novo Nordisk (NVO) is trailing both the S&P 500 and pharmaceutical stocks as a group (PPH) over the past three months.

Prices as of Last update : Among the weakest → trailing the market and pharmaceutical stocks
NVO 1M
−3.9%
S&P 500 1M
−10.3%
Funds that hold it
1
Weight in PPH
5.5%

Where Novo Nordisk stands now

As of 20 November 2026, Novo Nordisk had a good month against the S&P 500 after a weaker quarter. One month alone does not make a trend.

Inside its group, NVO lags: it is behind pharmaceutical stocks (PPH) over both the past month and three months. As a group, pharmaceutical stocks are gaining ground on the S&P 500 right now. The group is in transition, so the stock's place inside it matters more than usual.

Novo Nordisk is 5.5% of PPH, so its moves weigh on the fund. The thing to watch is the past month: a turn against the market usually shows there first.

NVO vs the S&P 500: returns

Novo Nordisk and the S&P 500 (SPY) side by side, over each window Zensei tracks.

Window
NVO
S&P 500
1 week−9.2%−8.6%
2 weeks−6.2%−5.9%
1 month−3.9%−10.3%
3 months−19.1%−9.7%
6 months−14.8%−7.0%
1 year−16.7%+6.9%

Prices as of · computed from daily adjusted closes · how we measure

Zensei Edge

NVO against pharmaceutical stocks, in depth

See the size of the gap between Novo Nordisk and pharmaceutical stocks (PPH) over every window, its momentum and its relative strength, and where it sits among pharmaceutical stocks.

See the full analysis

Which ETFs hold Novo Nordisk?

One fund that Zensei tracks holds NVO, by weight. The fund with the largest weight is its sector on this page.

Fund
Weight
PPHPharmaceutical StocksMain sector
VanEck Pharmaceutical ETF
5.5%

Novo Nordisk competitors

The largest other holdings of VanEck Pharmaceutical ETF (PPH), with their return over the past month.

Stock
Weight
1M
23.2%+5.1%
MRKMerck & Co Inc
12.5%−9.8%
5.1%−7.7%
MCKMckesson Corp
4.7%+3.8%
BMYBristol-Myers Squibb Co
4.5%−4.7%
CORCencora Inc
4.3%−1.0%
GSKGsk PLC
4.2%−4.8%
NVSNovartis AG
3.8%−2.1%
Each stock measured against the sector, with momentum and relative strengthUnlock with Premium

Novo Nordisk stock: common questions

Is Novo Nordisk stock beating the S&P 500?

As of 20 November 2026, Novo Nordisk (NVO) is down 3.9% over the past month. The S&P 500 is down 10.3% over the same month. Over three months, the stock is down 19.1% and the S&P 500 is down 9.7%.

Which ETFs hold Novo Nordisk?

As of 20 November 2026, one fund that Zensei tracks holds NVO. Its largest weight is in VanEck Pharmaceutical ETF (PPH), at 5.5%.

Who are Novo Nordisk's competitors?

As of 20 November 2026, the largest other holdings of VanEck Pharmaceutical ETF (PPH) are Eli Lilly (LLY), Merck & Co Inc (MRK), Pfizer (PFE), Mckesson Corp (MCK), Bristol-Myers Squibb Co (BMY). These are the stocks Novo Nordisk sits next to among pharmaceutical stocks.

Is Novo Nordisk doing better than other pharmaceutical stocks?

As of 20 November 2026, Novo Nordisk (NVO) is behind pharmaceutical stocks as a group (PPH) over the past three months. Zensei Edge shows the size of the gap, its momentum and its relative strength.

Recent changes

  1. ·Among the weakest → trailing the market and pharmaceutical stocks
  2. ·Trailing the market and pharmaceutical stocks → among the weakest
  3. ·Among the weakest → trailing the market and pharmaceutical stocks
  4. ·First tracked: among the weakest

Track Novo Nordisk against pharmaceutical stocks and the market

Zensei Edge maps 100+ sectors and themes against the S&P 500, with each stock inside them measured against its group.